IECM
CSTL icon

Intrinsic Edge Capital Management’s Castle Biosciences CSTL Stock Holding History

Intrinsic Edge Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-130,000
Closed -$2.83M – 117
2024
Q2 		$2.83M Sell
130,000
-20,000
-13% -$446K 0.26% 108
2024
Q1 		$3.32M Buy
+150,000
New +$3.26M 0.26% 99

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Intrinsic Edge Capital Management's CSTL Position: Q1 2025 in Review

Intrinsic Edge Capital Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 232,711 shares — an estimated $6.2M sold.

Intrinsic Edge Capital Management first reported a position in CSTL in Q1 2021 and held it in 15 quarters. The position peaked at $12.5M in Q2 2021. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Intrinsic Edge Capital Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 232,711 Castle Biosciences shares in Q1 2025, an estimated $6.2M.
  • Intrinsic Edge Capital Management first reported a position in Castle Biosciences in Q1 2021 and held it in 15 quarters.
  • Intrinsic Edge Capital Management's Castle Biosciences position peaked at $12.5M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Intrinsic Edge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.